 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TORONTO, ON / ACCESSWIRE / September 18, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ('FSD Pharma' or the 'Company'), a biopharmaceutical company...

FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated

TORONTO, ON / ACCESSWIRE / September 13, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ('FSD Pharma' or the 'Company'), a biopharmaceutical company...

FSD Pharma Announces Analyst Coverage Initiated by Singular Research

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (FSD Pharma or the Company), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today provides clarity and...

FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)

FSD Pharma (NASDAQ:HUGE Get Free Report) and VYNE Therapeutics (NASDAQ:VYNE Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst ...

FSD Pharma (NASDAQ:HUGE) & VYNE Therapeutics (NASDAQ:VYNE) Head to Head Comparison

Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment MarketTORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ('FSD Pharma' or...

FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023

VANCOUVER, British Columbia, Aug. 03, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic ...

InvestmentPitch Media Video Features FSD Pharma's Definitive Agreement Granting Exclusive Rights for Launch of UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink

Launch in the Consumer Market to be Led by Former Executives from Coca-Cola and Celsius HoldingsTORONTO, ON / ACCESSWIRE / August 2, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ('FSD Pharma' or the 'Company'), a biopharmaceutical company dedicated to building a...

FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (FSD Pharma or the Company), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announces that the...

Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (FSD Pharma or the Company), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announces that the Company...

FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock

FSD Pharma hires legal team to investigate suspected illegal trading

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Watchers	7,069
52-Wk Low	$0.6181
52-Wk High	$2.10

Market Cap	$22.8M
Volume (M)	14,075.00
52-Wk High	$2.10
52-Wk Low	$0.6181

HUGE FSD Pharma Inc - Ordinary Shares - Class B (Sub Voting)

About

Feed

News

Sentiment

Fundamentals